Ensysce Biosciences (ENSCW) Cash from Operations (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Cash from Operations of 1866179.0 for Q3 2025, down 82.9% year-over-year from 10914643.44 in Q3 2024, and up 31.06% quarter-over-quarter from 2706868.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Cash from Operations (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Cash from Operations data on file, last reported at 1866179.0 in Q3 2025.
- Cash from Operations for Q3 2025 came in at 1866179.0, down 82.9% year-over-year; the trailing twelve-month figure through Sep 2025 was 7044549.0 (up 17.52% YoY), and the FY2024 annual result was 7502700.0, up 30.4% from the prior year.
- Cash from Operations improved to 1866179.0 in Q3 2025 per ENSCW's latest filing, from 2706868.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 132312.0 in Q2 2021 and troughed at 6714311.0 in Q3 2022.
- A 5-year average of 2668039.84 and a median of 2706868.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 3256.08% in 2022, then soared 66.3% in 2023.
- A 5-year view of Cash from Operations shows it stood at 3767813.0 in 2021, then rose by 12.53% to 3295620.0 in 2022, then jumped by 45.33% to 1801875.0 in 2023, then surged by 57.59% to 764090.0 in 2024, then plunged by 144.24% to 1866179.0 in 2025.
- Business Quant data shows ENSCW's Cash from Operations at 1866179.0 in Q3 2025, 2706868.0 in Q2 2025, and 1707412.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.87 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -764,090.00 |
| Dec 31, 2024 | -764,090.00 |
| Sep 30, 2024 | -1.02 Mn |
| Sep 30, 2024 | -1.02 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Jun 30, 2023 | -3.11 Mn |
| Jun 30, 2023 | -3.11 Mn |